Alessandra Curioni‐Fontecedro

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma

Karīna Siliņa, Alex Soltermann, Farkhondeh Movahedian Attar et al. · Cancer Research · 2017 · 423 citations · Full text

Medicine, Oncology, Pathology +17

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni et al. · Annals of Oncology · 2020 · 273 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

Oliver Gautschi, Julie Milia, Bastien Cabarrou et al. · Journal of Thoracic Oncology · 2015 · 186 citations · Full text

Medicine, Molecular Medicine, Oncology +10